- Home
- BRLT vs BNR Comparison
BRLT vs BNR Comparison
Compare BRLT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- BNR
- Stock Information
- Founded
- BRLT 2005
- BNR 2014
- Country
- BRLT United States
- BNR China
- Employees
- BRLT N/A
- BNR N/A
- Industry
- BRLT Consumer Specialties
- BNR Medical Specialities
- Sector
- BRLT Consumer Discretionary
- BNR Health Care
- Exchange
- BRLT Nasdaq
- BNR Nasdaq
- Market Cap
- BRLT 36.6M
- BNR 38.3M
- IPO Year
- BRLT 2021
- BNR 2020
- Fundamental
- Price
- BRLT $2.51
- BNR $8.04
- Analyst Decision
- BRLT Hold
- BNR
- Analyst Count
- BRLT 2
- BNR 0
- Target Price
- BRLT $1.80
- BNR N/A
- AVG Volume (30 Days)
- BRLT 137.7K
- BNR 17.2K
- Earning Date
- BRLT 11-05-2025
- BNR 12-02-2025
- Dividend Yield
- BRLT 9.84%
- BNR N/A
- EPS Growth
- BRLT N/A
- BNR N/A
- EPS
- BRLT N/A
- BNR N/A
- Revenue
- BRLT $422,218,000.00
- BNR $74,862,782.00
- Revenue This Year
- BRLT $5.45
- BNR $136.32
- Revenue Next Year
- BRLT $3.28
- BNR N/A
- P/E Ratio
- BRLT N/A
- BNR N/A
- Revenue Growth
- BRLT N/A
- BNR 5.20
- 52 Week Low
- BRLT $1.25
- BNR $2.18
- 52 Week High
- BRLT $3.10
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- BRLT 58.57
- BNR 42.31
- Support Level
- BRLT $2.15
- BNR $8.18
- Resistance Level
- BRLT $2.54
- BNR $8.62
- Average True Range (ATR)
- BRLT 0.18
- BNR 0.46
- MACD
- BRLT 0.06
- BNR -0.14
- Stochastic Oscillator
- BRLT 83.75
- BNR 2.26
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.